Teva Rejected by Justice Roberts on Generic Copaxone Delay
This article is for subscribers only.
A U.S. Supreme Court justice rejected Teva Pharmaceutical Industries Ltd.’s bid to block generic versions of its Copaxone multiple-sclerosis drug while the court hears the company’s appeal in a patent clash.
The rebuff by Chief Justice John Roberts leaves Teva open to generic competition as soon as next month. Mylan Inc., Momenta Pharmaceuticals Inc. and Novartis AG’s Sandoz are positioned to start selling generic Copaxone in late May, although they would risk having to pay damages if Teva ultimately wins its patent-infringement case. Momenta and Sandoz are working together on a generic version of the drug.